ExoScreen as a Novel Liquid Biopsy Platform for Detecting Cancer-Specific ExosomesFriday, 8 April 2016 at 08:30 Add to Calendar ▼2016-04-08 08:30:002016-04-08 09:30:00Europe/LondonExoScreen as a Novel Liquid Biopsy Platform for Detecting Cancer-Specific ExosomesExosomes and Liquid Biopsies Asia 2016 in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com A highly sensitive and rapid analytical technique for profiling circulating EVs/exosomes directly from blood samples of patients has also been established that uses two types of antibodies to capture two specific antigens residing on EVs and can be detected by photosensitizer beads. Using this system, higher signal detecting CD147 and CD9 double-positive EVs were observed in serum from colorectal cancer (CRC) patients compared with that in serum from healthy donors. A part of sera from CRC patients including stage I and II were positive for CD147, although both CEA and CA19-9 positive serum could not be found in those patients. On the basis of these results, this new ExoScreen technology may enable the effective diagnosis of cancer. |